On October 8, 2026, a Phase 3 clinical trial titled "Stratification and Treatment in Early Psychosis Study - PROMOTE" was listed with a status of not yet recruiting. The trial is registered under identifier NCT07434973 on ClinicalTrials.gov. This update relates to substance P, which currently holds unapproved research status. The trial record indicates a Phase 3 designation, reflecting its stage within the clinical development process. As of this date, the study has not begun enrolling participants, according to the registration status. No additional details regarding trial design, participant criteria, or timelines were included in this update. No outcomes, efficacy data, or safety findings have been reported, since the trial has not started recruitment. This brief reflects only the information available in the trial registration as of the stated date. Interested readers should consult the official registry listing for the most current information on trial progress. For additional background on substance P and its research status, readers can refer to the compound overview.
Substance P Trial PROMOTE (NCT07434973) Listed as Not Yet Recruiting
See the full substance p overview
Source: https://clinicaltrials.gov/study/NCT07434973